CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

The purpose of this study is to assess the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant-who, as assessed by investigators, are improbable desensitization through conventional treatments (e.g., plasmapheresis and immunoadsorption)- with or without living donors.

NCT Number	NCT07350837
Lead Sponsor	Tongji Hospital
Conditions	Highly Sensitized Patients Awaiting Kidney Transplant
Enrollment	12 participants
Start Date	2026-01-28
Primary Completion	2026-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-16